April 3, 2025
The life sciences industry continues to face significant cost and operational pressures, among which include substantial challenges in sourcing key raw materials used in the production of many of our products, the cost of attracting and retaining skilled labor continuing to rise, and uncertainty introduced by the current global economic climate, as seen in factors such as rising inflation and significant volatility in foreign exchange rates. Because of these pressures, it will be necessary to implement a modest price adjustment in order to maintain the quality and high standard of our products and services.
Please know this decision is not being taken lightly. We are taking significant efforts to manage these cost pressures and in many cases are absorbing much of the impact of these challenges. We have held prices on a significant portion of our portfolio; however, where we are making changes, these will be effective from 1st April 2025.
Despite these challenges, we remain committed to delivering the exceptional quality and service you have come to expect from us. The price adjustment will enable us to continue investing in our products and services, ensuring that we can support you with the most reliable and highest-quality diagnostic and genomic products.
For most customers, there will be no further action will be required. However, if your systems require updates to reflect the new pricing, we will work closely with you to ensure minimal disruption to your ordering process. In cases where pricing is governed by contract or agreement with specific terms, we will continue to honour those terms as agreed.
We understand that price changes can be difficult, and we are here to address any questions or concerns you may have. Please feel free to contact me for further assistance.
Thank you for your understanding and continued partnership. We look forward to continuing to serve you.
Yours sincerely,
Tony Hill
Director, International Distribution